Somatic cell reprogramming for Parkinson's disease treatment
Ibrain · 2025-03 · 11 (1) · 59-73
DOI: 10.1002/ibra.12189 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ibrain, online erschienen am 04.01.2025. Verfasst von Xiaozhuo Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Institute of Primate Translational Medicine Kunming University of Science and Technology Kunming China. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Parkinson's disease (PD) is a neurodegenerative disease characterized by degeneration of dopamine neurons in the substantia nigra pars compacta. The patient exhibits a series of motor symptoms, such as static tremors, which impair their capacity to take care for themselves in daily life. In the late stage, the patient is unable to walk independently and is bedridden for an extended period of time, reducing their quality of life significantly. So far, treatment methods for PD mainly include drug therapy and deep brain stimulation. Pharmacotherapy is aimed at increasing dopamine (DA) levels; however, the treatment effect is more pronounced in the short term, and there is no benefit in improvement in the overall progression of the disease. In recent years, novel therapeutic strategies have been developed, such as cell reprogramming, trying to generate more DA in PD treatment. This review mainly discusses the advantages, methodology, cell origin, transformation efficiency, and practical application shortcomings of cell reprogramming therapy in PD strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Institute of Primate Translational Medicine Kunming University of Science and Technology Kunming China.
- Living Systems Institute University of Exeter Exeter UK.
- College of Traditional Chinese Medicine Shandong Second Medical University Weifang Shandong China.
ORCID-Profile: Kevin Fang, Fengping Wang
Zitieren
APA
Li, X., Fang, K., & Wang, F. (2025). Somatic cell reprogramming for Parkinson's disease treatment. Ibrain, 11(1), 59-73. https://doi.org/10.1002/ibra.12189
Vancouver
Li X, Fang K, Wang F. Somatic cell reprogramming for Parkinson's disease treatment. Ibrain. 2025;11(1):59-73. doi:10.1002/ibra.12189
BibTeX
@article{Li2025,
author = {Li, Xiaozhuo and Fang, Kevin and Wang, Fengping},
title = {Somatic cell reprogramming for Parkinson's disease treatment},
journal = {Ibrain},
year = {2025},
volume = {11},
number = {1},
pages = {59--73},
doi = {10.1002/ibra.12189}
}
EUVIMED